MMP8產(chǎn)品信息
英文名稱:Matrix metalloproteinase 8
中文名稱:基質(zhì)金屬蛋白酶-8
靶點(diǎn)別稱:MMP8
物種:Human/Mouse
屬性:Protein
標(biāo)記:Unconjugated
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Supplied as 0.2 μm filtered solution in 50 mM Tris,150 mM NaCl,pH8.0 with trehalose as protectant.
Contact us for customized product form or formulation.
運(yùn)輸(Shipping)
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存儲(chǔ)(Storage)
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 3 months under sterile conditions.
MMP8分子背景
Matrix metalloproteinase-8(MMP-8)also known as neutrophil collagenase and CLG1,is a member of matrix metalloproteinases (MMPs) family,which degrade components of the extracellular matrix (ECM) and play essential roles in various physiological processes as well as pathological processes. MMP-8 may affect the metastatic behavior of breast cancer cells through protection against lymph node metastasis, underlining the importance of anti-target identification in drug development. MMP-8 in the tumor may have a protective effect against lymph node metastasis.
關(guān)鍵字: MMP8;MMP8蛋白;MMP8重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。